Novo Integrated Sciences, Inc. (OTC:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints providing services and product innovation, today reported its financial results for the fiscal year ended August 31, 2024. Robert Mattacchione, the Company's CEO and Board Chairman, stated, "The Company remains committed to the commercialization of its proprietary product offerings and the expansion and delivery of its essential services and solutions to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the third fiscal quarter ended May 31, 2024. Robert Mattacchione, Novo's CEO and Board Chairman, stated, "The Company's fiscal year 2024 third quarter emphasized maximizing operational efficiencies for all business units. The Company continues to work with certain prospective financial partners to close previously announced non-traditional financing opportunities to raise foundation

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today that it has received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit ("SBLC"). The initial disbursement represents the first payment as per the arrangement creating a release of lien resulting in the subsequent final advance to the Company. With this initial disbursement the Company expects final distribution to follow on or before August 2. As previously reported, the Company entered into an application for the monetizing program whereby the Company is projected to receive gross funding proceeds of approximately $78 million under the SBLC monetizatio

4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)

4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)

4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)

8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)

8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)

8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announces today Mr. Robert Oliva has been appointed as the Company's new President. Mr. Oliva succeeds Mr. Christopher David, who remains as the Company's Chief Operating Officer and as a member of the Company's Board of Directors. Mr. Oliva has over 35 years of ownership and proven business development with expertise in manufacturing related operations. Mr. Oliva is expected to advance the Company's product-related operational efficiency while managing aggressive, yet sustainable growth and improving margins. Robert Mattacchione, the Company's CEO and Board Chairman, stated, "The addition of Mr. Oliva comes at a tim

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announces that Dr. Indrajit "Indra" Sinha, Ph.D. has been appointed as Novo's Chief Science Officer, effective June 24, 2021. Dr. Sinha brings over 25 years of experience in various areas of cross-disciplinary translational research, drug development, biotechnology, technology transfer, and biopharmaceutical compliance. His work has been extensively published in highly reputed peer reviewed journals. Through his passion for utilizing under-appreciated technologies and applying them in innovative ways to achieve previously unattainable outcomes, he has created various intellectual property and patents. Robert Mattacchio

Dr. Joseph M. Chalil, MD, MBA, FACHE Appointed Chief Medical Officer and the New President of Novomerica Health Group Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, today announced the Company has completed the acquisition of Clinical Consultants International LLC ("CCI"), a global consulting firm, based in Boca Raton, Florida, specializing in providing value-added services for the pharmaceutical, biotech, healthcare management, hospital management, medical marketing and strategic planning, health policy, and medic

Iodine, an essential nutrient, when in aerosolized aqueous form can be safely ingested to kill bacteria and deactivate various viruses Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, announced today it has acquired 91% of Terragenx and the intellectual property portfolio for the unique formulation and manufacturing capability to produce a water-soluble iodine micro-nutrient that is FDA and Health Canada approved for over-the-counter and e-commerce distribution (the "Iodine IP and Patents"). Iodine is a naturally oc

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today Novo Healthnet Limited, a wholly owned subsidiary of the Company ("NHL"), completed the acquisition of Acenzia Inc., a Windsor Canada based company that provides nutraceutical health solutions through advanced bio-science research and development, proprietary manufacturing, and personalized diagnostics. The all-share transaction, which closed on June 24, 2021, is valued at $14,884,039, or $3.91 per share, and is subject to purchase price adjustment within 90 days of the closing date pending completion of an audit and working capital requirement provisions. Robert Mattacchione, Novo's Chairman and CEO, st

SC 13G/A - Novo Integrated Sciences, Inc. (0001138978) (Subject)

SC 13G/A - Novo Integrated Sciences, Inc. (0001138978) (Subject)

SC 13G - Novo Integrated Sciences, Inc. (0001138978) (Subject)